高级检索
当前位置: 首页 > 详情页

Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua

文献详情

编号/登记号:
注册时间:
研究开始时间:
研究结束时间:
项目类型:
本院角色:
多中心研究:
招募状态:
试验分期:
研究疾病/适应症:
研究类型:
研究负责人:
研究单位: [1]Beijing Tongren Hospital [2]Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. [3]Peking University People's Hospital [4]West China Hospital,Sichuan University [5]Qingdao Municipal Hospital [6]No. 202 Hospital of PLA (General Hospital of Northern Theater Command ) [7]First Hospital of Shanxi Medical University [8]Second Hospital of Shanxi Medical University

研究目的:
Allergic rhinitis (AR) is a common disease of nasal mucosa, affecting 10% to 40% of the population globally. Allergen specific immunotherapy (AIT) is the only etiological treatment available for AR.Traditionally, AIT is divided into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Artemisia annua is one of the most important allergen that is responsible for seasonal AR in China during July and October. The trial is a randomized, double-blind, placebo-controlled, multicentred, phase III trial. 702 subjects with allergic rhinitis caused by Artemisia pollen were recruited and randomized to the immunotherapy group and placebo group.

资源点击量:21434 今日访问量:0 总访问量:1221 更新日期:2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)